First Growth Capital LLC Takes Position in Amgen Inc. $AMGN

First Growth Capital LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, Holdings Channel reports. The fund acquired 2,082 shares of the medical research company’s stock, valued at approximately $681,000.

Several other large investors also recently made changes to their positions in AMGN. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock worth $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. State Street Corp increased its holdings in shares of Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after acquiring an additional 1,287,310 shares in the last quarter. Capital World Investors raised its position in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Capital International Investors raised its position in shares of Amgen by 1.5% during the third quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Amgen by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after purchasing an additional 1,035,779 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Trading Down 1.2%

NASDAQ AMGN opened at $337.60 on Friday. The stock has a market capitalization of $182.21 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 3.43 and a beta of 0.42. Amgen Inc. has a one year low of $267.83 and a one year high of $391.29. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The business’s fifty day moving average is $340.96 and its 200-day moving average is $345.81.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.38 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective on the stock. UBS Group lifted their price objective on shares of Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a report on Monday, April 13th. Morgan Stanley boosted their target price on shares of Amgen from $332.00 to $340.00 and gave the stock an “equal weight” rating in a research report on Tuesday, June 9th. Wells Fargo & Company upped their target price on shares of Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, March 19th. Finally, Wall Street Zen raised shares of Amgen from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $354.42.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.85% of the stock is currently owned by insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.